The global pharma meeting point
From 28 to 30 October 2025, Frankfurt becomes the beating heart of the pharmaceutical world with CPHI Europe. With more than 62,000 attendees and 2,400 exhibitors, the event is a unique platform to connect, exchange knowledge, and explore innovation.
GenEvolution will proudly take part in this international gathering to highlight its cutting-edge solutions in nitrosamine risk evaluation and impurities testing—two critical topics for today’s pharma industry.
Why nitrosamines and impurities matter
In recent years, nitrosamines contamination has emerged as a major regulatory and safety concern, leading to recalls and stricter guidance worldwide. Similarly, the control of genotoxic impurities is now a cornerstone of quality assurance, directly impacting patient safety and compliance with EMA and FDA standards.
GenEvolution brings deep expertise in:
- Risk assessment and prediction of nitrosamine formation.
- Advanced in vitro testing to evaluate genotoxic impurities.
- Regulatory guidance alignment, ensuring compliance with evolving EMA and ICH requirements.
GenEvolution’s added value
What sets GenEvolution apart is its integrated scientific and regulatory approach. Our team combines toxicological expertise with state-of-the-art laboratory models—including reconstructed human tissues and predictive assays—allowing faster, more reliable decision-making for our clients.
By partnering with GenEvolution, pharma companies can:
- Anticipate regulatory expectations.
- Reduce the risk of costly product recalls.
- Accelerate time-to-market with safe and compliant products.
Meet us at CPHI Frankfurt 2025
At our booth, visitors will discover how GenEvolution supports the industry in tackling nitrosamines and impurities through a combination of science, innovation, and compliance expertise.
We look forward to connecting with industry leaders, partners, and innovators in Frankfurt to shape the future of safer pharmaceuticals.
